Tolaney, S. M., Azambuja, E. D., Kalinsky, K., Loi, S., Kim, S., Yam, C., Rapoport, B., Im, S., Pistilli, B., Mchayleh, W., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas-Junior, R., Bofill, J. S., Afshari, M., Gary, D., Wang, L., Lai, C., Schmid, P. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2508959